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Aim. To investigate the eﬀects of exogenous antioxidant copper zinc superoxide dismutase (Cu/Zn SOD) on oxidative stress in the
experimental model of diabetes mellitus (DM). Methods. Twenty eight male Wistar rats divided in four groups were used: control
(CO), controls treated with SOD (CO + SOD), diabetics (DM), and diabetics treated with SOD (DM + SOD). SOD (orgotein,
13mg/Kg body weight was administered. DM was induced by a single streptozotocin injection (i.p., 70mg/kg), and 60 days later,
we evaluated liver oxidative stress. Results. Liver lipoperoxidation was increased in the DM group and signiﬁcantly decreased in
the DM + SOD group. Nitrite and nitrate measures were reduced in the DM and increased in the DM + SOD group, while iNOS
expression in the DM group was 32% greater than in the CO and 53% greater in the DM + SOD group than in the DM group
(P<. 01). P65 expression was 37% higher in the DM (P<. 05), and there was no signiﬁcant diﬀerence between the DM and DM
+S O Dg r o u p s .Conclusion. SOD treatment reduced liver oxidative stress in diabetic animals,even though it did not change NFκB.
SOD also increased NO, probably by the increased dismutation of the superoxide radical. The iNOS expression increase, which
became even more evident after SOD administration.
1.Introduction
Diabetes mellitus (DM) is an endocrine-metabolic disorder
of increasing incidence and clinical relevance, contributing
to high morbidity and mortality rates [1]. Due to population
aging, urbanization, increased prevalence of obesity, and
physicalinactivity, thenumberofindividualsaﬀectedby DM
is increasing in many parts of the world [2]. In view of this
growing incidence, the study of the physiological routes of
DM becomes crucial for the emergence of novel therapeutic
procedures [3].
Fourphysiopathologicalpathwaysare involvedand cause
thechroniccomplicationsofthedisease:thepolyolspathway,
protein kinase C activation, increase in the hexosamine
ﬂow rate, and the advanced glycation end-products (AGE)
pathway. Although the disorder presents diﬀerent routes of
activation, oxidative stress (OE) is present in all the above-
mentioned pathways.
Strategies to reduce the formation of superoxide anion
(O−·) and thus oxidative stress are relevant to the treatment
of DM [4]. The action of O−· scavengers is performed
by a group of antioxidant enzymes called superoxide dis-
mutases (SODs), which catalyze the dismutation of O−·
into hydrogen peroxide (H2O2)a n do x y g e n( O 2)e ﬃciently
and speciﬁcally. Mammal tissues have 3 SODs isoforms:
Cu/Znsuperoxidedismutase (SOD1),MnSOD(SOD2),and
extracellular SOD (EC-SOD, or SOD3). SOD1 is a 32kDA
homodimer cell protein containing copper and zinc, and2 Experimental Diabetes Research
it is present in the cytosol, nucleus, peroxisomes, and
mitochondrial membrane. Its primary function is to reduce
the steady intracellular concentration of superoxide [5].
At the same time McCord and Fridovich were purifying
SOD, another team of researchers puriﬁed orgotein [6], an
anti-inﬂammatory compound identical to SOD. Orgotein
is the generic name adapted by the USAN Council (U.S.
Adopted Names Council) for Cu/Zn superoxide dismu-
tase (SOD). This compound is obtained from bovine
liver through a process involving thermal treatment, enzy-
matic digestion of other proteins, and puriﬁcation of the
homogenate through ionic exchange chromatography [7].
In the 1980s, approximately six million doses of SOD were
administered to patients in Europe [8]. A number of clinical
trials showed the eﬀects of using orgotein in inﬂammatory
disorders.Amongtheseitishighlightedtheuseoforgoteinin
acute complications secondary to radiotherapy and intense
radiation in the head, neck [9]a n dp e l v i s[ 10], in Peyronie’s
disease [11, 12], arthritis [7, 13, 14], bladder contracture
[11, 15], multiple sclerosis [16], and hypertrophic scars, and
cheloids [17].
The liver is the main organ of oxidative and detoxifying
processes as well as free radical reactions; in many diseases,
biomarkers of oxidative stress are elevated in the liver at
an early stage. Because liver is subjected to ROS-mediated
injury in diabetes, our experiments were performed to
investigate the potential protective eﬀects of SOD treatment
on liver oxidative stress and p65 and iNOS expression in an
experimental model of chronic hyperglycemia.
2.Materialsand Methods
2.1. Animals and Experimental Protocol. The experimental
protocol was according to the norms established by the
Ethical Research Committee of Health of the Research and
Postgraduate Group of the Hospital de Cl´ ınicas of Porto
Alegre, as well as the recommendations of the Principles for
Research Involving Animals (NAS).Twenty-eight male Wistar
rats obtained from the breeding colony of the Basic Health
Sciences Institute of the Federal University of Rio Grande
do Sul (UFRGS) were used. Their mean weight was 200–
300grams (g) at the start of the trials. They were kept at
a room with controlled temperature (22 ± 4◦C) and at a 12h
light/dark cycle (light from 7 a.m to 7 p.m).
DM was induced by a single intraperitoneal (i.p.) injec-
tion of streptozotocin—STZ (Sigma Chemical Company, St.
Louis, MO, USA) at a dose of 70mg/Kg body weight [18].
STZ was dissolved in citrate sodium buﬀer (0.1M, pH 4.5)
a n dc i t r i ca c i d( 0 . 1 M ,p H4 . 5 )a n da d m i n i s t e r e di nt h e
left abdominal region about 10min after dilution in buﬀer
solution. The animals in the control group were given only
sodium chloride (NaCl 0.9%) i.p. at the same volume of the
buﬀer that was used to dissolve STZ.
Twenty-eight male Wistar rats were divided in four
groups: control (CO), controls treated with SOD (CO +
SOD), diabetics (DM), and diabetics treated with SOD (DM
+ SOD). Superoide dismutase (Ontosein-orgotein-, Lab.
Tedea-Meiji Farma, S. A., Madrid-Spain) was used at a dose
of 13mg/Kg body weight for the last seven days of the trial
and was administered subcutaneouslyas described elsewhere
[19]. On day 60, the animals were sacriﬁced and their liver
removed for posterior analyses.
After 60 days of DM, the animals were deeply anes-
thetized and killed by exsanguination. Blood was withdrawn
from the retro-orbital sinus and centrifuged for 15 minutes
for glycemia determination, and the liver was removed in
portions and frozen at −80◦C for posterior measurements.
2.2. Biochemical Analyses and Oxidative Stress
2.2.1. Glycemia. For glycemia determination the colorimet-
ric enzymatic test (Kit ENZI-COLOR, Bio Diagn´ ostica) was
used, in which a reagent was mixed with 20μLo ft h e
plasma sample and read in spectrophotometer (CARY 3E —
UV-Visible Spectrophotometer Varian) with wavelength of
500 nm. Animals with blood glucose concentration above
250mg/dL were considered as diabetics.
2.2.2.Oxidative Stress. Theliverwashomogenizedwith9mL
of phosphate buﬀer (KCL 140mM, phosphate 20mM pH
7.4) per tissue gram. Protein concentration in the liver
homogenateswas determined usingbovinealbuminsolution
as described by Lowry [20].
Liver peroxidation was determined by the thiobarbituric
acid reactive substances (TBA-RS) assay [21].
Fordeterminationofantioxidantenzymesuperoxidedis-
mutase (SOD) we used the technique based on inhibition of
adrenochrome formation in epinephrine autoxidation [22],
and antioxidant enzyme catalase activity was determined by
measuring the exponential disappearance ofH2O2 at 240nm
and was expressed as pmoles/mg protein [23].
The determination of selenium-dependent glutathione
peroxidase (GPx) was obtained through a method that
consists in measuring NADPH oxidation by glutathione
reductase [24].
2.3. Nitrite and Nitrate Measures. Total nitrites was mea-
sured by Griess’s method. The samples were incubated
with enzymatic cofactors (Tris 1mol/L, pH 7.5; NADPH
0.02mmol/L), glucose 6-phosphate, (G6P) 5mmol/L, glu-
cose 6-P dehydrogenase (G6PDH) 10U/ml, and nitrate
reductase (1.75U/ml; Sigma, St. Louis, MO) for one
hour to convert nitrate into nitrite at room temperature.
Nitrites were determined by the reaction of samples with
Griess’s reagent (1% sulfanilamide, 0.1% naphthylenedi-
amine 2.3mL phosphoric acid 85%). Total tissue nitrite (ini-
tial nitrite plus the nitrite produced from sodium reduction)
was estimated at 540nm, from a standard curve of sodium
nitrite (10−8 a1 0 −3 mol/L). The results were expressed as
mmol/L [25].
2.3.1. Western Blot. P r o t e i ne x t r a c t i o na n dW e s t e r nb l o t t i n g
wereperformedasdescribedelsewhere [26].Themembranes
were incubated with anti-iNOS polyclonal antibody and
speciﬁc anti-p65 antibody (Santa Cruz Biotechnology).
Binding to the primary antibody was detected through
rabbit anti-immunoglobulin bound to HRP (DAKO A/S,
Glostrup, Denmark). Protein detection was performed byExperimental Diabetes Research 3
Table 1: Changes in body weight and glycemia.
N Weight (g) Glycemia
(mg/dL)
CO 5 332.8 ± 27.66 237.95 ± 54.27
CO + SOD 6 312 ± 25.45 217.23 ± 27.45
DM 8 299.33 ± 46.17 481.29 ± 84.15
DM + SOD 9 266.28 ± 28.23 397.43 ± 29.15
Data appear as mean ± SD. CO: Control SOD: superoxide dismutase DM =
Diabetes Mellitus P<. 01—CO versus DM + SOD; CO + SOD versus DM +
SOD P<. 001—CO versus DM; CO + SOD versus DM.
chemiluminescence using a commercial kit ECL (Amersham
Pharmacia Biotech, Little Chalfont, Great-Britain) exposing
the membrane to this commercial mixture for one minute.
A cassette tape was subsequentlyintroduced with developing
ﬁlm (Amersham Hyperﬁlm ECL, UK) for about 2 minutes.
After washing the ﬁlm, the bands were quantiﬁed by
densitometry using program Scion Image 4.02 for Windows
(Scion Corporation, Frederick, USA), with results being
expressed in relation to control percentage (100%).
2.3.2. Statistical Analysis. Data were presented as mean ±
standard deviation (SD) and analyzed with the Statistical
Package for the Social Sciences version 15.0 (SPSS-15.0).
Variables were tested for normality by the Kolmogorov-
Smirnov test. One-way analysis of variance (ANOVA) was
usedforinter-group diﬀerences.The studentNewman-Keuls
posttest was used for parametric variables, and Person’s test
was used for correlation of variables. The levelof signiﬁcance
was 5% (P<. 05).
3.Results
Exogenous SOD administration failed to reduce glycemia
in diabetic rats. There was a signiﬁcant decrease in animal
weight in the DM group, and SOD treatment (DM + SOD)
did not reverse this condition (Table 1). The DM group
showed a signiﬁcant increase in liver lipoperoxidation and
treatment with exogenous SOD signiﬁcantly reduced these
values (Table 2). SOD and GPx activities were reduced in the
DM group and the DM + SOD group showed an increase
in enzymatic activities. Catalase activity was increased in the
DM group and the treatment with SOD restored the activity
values close to those of the CO group. Nitrite and nitrate
measures were reduced in the DM group and were increased
after treatment with SOD (Table 2). In addition, a positive
correlation was found between SOD activity and high levels
of nitrites and nitrates (P = .023; r = 0.565).
INOS expression was increased in the DM group as
compared to the CO group, and the SOD-treated group
showed an increase as compared to the DM group itself
(Figure 1). P65 had greater expression in the DM (P<. 05)
and no statistical diﬀerence as compared to the diabetic and
SOD-treated groups (Figure 2).
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Figure 1: Eﬀect of streptozotocin-induced diabetes and SOD on
liver iNOSprotein by Westernblotanalysis.Proteins were separated
in SDS-polyacrylamide gel at 12% and incubated with anti-iNOS
antibody. (a) CO versus DM P<. 0 5 ;( b )D Mv e r s u sD M+S O D
P<. 01; (c) CO + SOD versus DM + SOD P<. 001; (d) CO + SOD
versus DM P<. 01; (e) CO + SOD versus DM + SOD P<. 001.
4.Discussion
The results of the present study conﬁrmed previous studies
which described increased liver oxidative stress in the model
of experimental diabetes mellitus [27]. These studies showed
alterations in the activity of antioxidant enzymes associated
with liver oxidative injury. Being rich in mitochondria
to perform metabolic functions, the liver is a crucially
important organ, and in a chronic hyperglycemic state the
liver oxidative stress is considered a relevant process [28].
Exogenous SOD administration did not aﬀect the
glycemic values of diabetic animals. This ﬁnding contradicts
a few results from previous studies which used antioxidants
in the treatment of experimental DM [29]. Such diﬀerent
results could be due to the time and duration of the SOD
treatment, which in our study occurred during the last week
of a 60-day trial, whereas in other studies it was concomitant
with induction.
SOD is an important antioxidant enzyme which rapidly
catalyzes the dismutation of superoxide anion (O−·)a n d
thus acts as a ﬁrst line antioxidant defense. In the case of
SOD deﬁciency or increased superoxide production, it reacts
with nitric oxide to produce peroxynitrite (ONOO−), which
isapotentoxidantandnitrosating agentthatcancausedirect
damage to proteins, lipids, and DNA [8].
Since oxidative stress results from an imbalance between
thegenerationofreactiveoxygenspeciesand/ornitrogenand
the body’s endogenous and exogenous defense ability, the
study of the activity of antioxidant enzymes in DM becomes
highly important.
In the present study, a signiﬁcant increase was found
in liver peroxidation in the DM group and a reduction4 Experimental Diabetes Research
Table 2: Oxidative stress, antioxidant enzyme activity and total nitrites and nitrates (NOx).
CO (5) CO + SOD (6) DM (8) DM + SOD (9)
ANOVA
CO versus DM DM versus DM + SOD
TBARS (nmols/mg
prot.) 0.20 ± 0.03 0.21 ± 0.04 0.36 ± 0.15 0.18 ± 0.04 P<. 05 P<. 01
SOD (U/mg prot.) 37.53 ± 11.61 39.83 ± 10.53 22.74 ± 4.23 62.73 ± 20.18 P<. 05 P<. 0001
CAT (pmols/mg
prot.) 0.18 ± 0.02 0.21 ± 0.06 0.27 ± 0.03 0.17 ± 0.03 P<. 01 P<. 001
GPx (nmols/mg
prot.) 0.91 ± 0.06 0.75 ± 0.19 0.53 ± 0.10 0.76 ± 0.16 P<. 01 P<. 05
NOx (mM
NO3+NO2) 2.32 ± 0.54 2.24 ± 0.27 1.47 ± 0.61 2.28 ± 0.20 P<. 05 P<. 05
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Figure 2: Eﬀect of streptozotocin-induced diabetes and SOD on
p65 protein by Western blot analysis. The nuclear fraction protein
was separated in SDS-polyacrylamide gel at 12% and incubated
with anti-p65 antibody. (a) CO versus DM P<. 05; (b) DM versus
DM + SOD P>. 05; (c) CO + SOD versus DM + SOD P>. 05; (d)
CO + SOD versus DM P>. 05; (e) CO + SOD versus DM + SOD
P>. 05.
in this oxidative stress marker following treatment with
exogenous SOD, as well as reduced antioxidant enzymes
SOD and GPx activities in DM and a signiﬁcant increase
after treatment. The reduction in SOD activity in the DM
groupcan beexplained by glycationin theEC-SODheparin-
binding domain. This domain anchors the protein to the
endothelial cells surface and extracellular matrix of blood
vessels [30, 31]. The aﬃnity with heparin can be modulated
by hyperglycemia, through the nonenzymatic glycation of
EC-SOD lysine residues located in the heparin-binding
domain. This glycation determines loss of heparin aﬃnity
but maintains SOD enzymatic activity in the extracellular
medium. However, studies performed in diabetic patients
show high serum levels of glycated EC-SOD and reduction
in the arterial activity of this enzyme. These ﬁndings could
be explained by glycation inhibiting the intracellular Cu/Zn
SOD and this process indirectly aﬀecting EC-SOD function
[30, 31]. NO and its reactive species can cross the cell
membrane and modulate the relaxation of smooth muscle
and vascular tone response. In the extracellularmedium, NO
can establish a connection with great quantity of superoxide
resulting from an extensive process of protein glycation in
DM. Therefore, decreased vascular concentration of EC-
SOD, reduced intracellular SOD activity, and increased
production of superoxide anion are directly involved in the
pathogenic process of DM, and the use of exogenous SOD
may have a beneﬁcial eﬀect of reversing this process.
Peixoto et al. (2009) investigated the eﬀects of a mimetic
of SOD, the tempol, on renal oxidative stress in diabetic
hypertensive rats. The study showed improvements in renal
function accompanied by improvements in redox status with
the use ofexogenous enzyme. The improvement ofthe redox
state can be proved by the increased expression of EC-SOD
in renal cortex of animals treated with the SOD mimetic,
in addition to reducing the generation of reactive oxygen
species [32].
A number of studies have shown the involvement of
NO and superoxide anion radical in the physiopathological
process of chronic complications in DM [33]. Moreover,
NO and other related free radicals and oxidative species
are the greatest agents of β-pancreatic cell necrosis. In our
study, there was evidence of a reduction in NO metabolites
in the DM group and an increase in it after exogenous
SOD administration. In addition, antioxidant enzyme SOD
activity was found to be positively correlated with nitrite and
nitrate levels (P = .023; r = 0.565).
These ﬁndings show a greater availability of nitric
oxide in diabetic animals treated with SOD, probably due
to increased activity of antioxidant enzyme SOD. From
these results one can establish a direct action from SOD
dismutating the superoxide radical and an indirect action of
this drug related to NO [9, 33]. Coppey et al. demonstrated
the eﬀect of treatment with a SOD functional mimetic
M40403 to prevent vascular and neural complications in
experimental diabetes. These studies provide additional
evidence that diabetes-induced oxidative stress and the
generation of superoxide and perhaps peroxynitrite may
be partially responsible for the development of diabetic
complications [34].Experimental Diabetes Research 5
Through an imbalance in the redox state, DM triggers
the activation of nuclear transcription factors such as NFκB.
The nuclear transcription factor NFκBb i n d st oD N Aa s
a heterodimer of 50kDa (p50) and 65kDa (p65). The
p65 subunit is responsible for the activation potential of
NFκB[ 35]. NFκB activation is responsible for an increase
in iNOS expression. In our study, as well as in Dias et al.
[27], there was increased expression of nuclear p65 and
iNOS, showing NFκBa c t i v a t i o ni ne x p e r i m e n t a lD M .
However, the use of exogenous SOD did not reduce p65
and increased iNOS expression. Experimental studies have
demonstrated that the use of antioxidants can reduce
oxidative stress, inhibit the activation of redox-dependent
transcription factors [27], and the iNOS expression [36].
In our study, exogenous SOD administration determined
changes to antioxidant enzyme activity and oxidative
stress, but such changes did not cause p65 modiﬁcation.
There was iNOS expression increase, which became even
more evident after SOD administration. The results of
exogenous SOD administration in our experimental
model diﬀer from those of other in vitro studies showing
iNOS regulation by antioxidant enzyme SOD [37, 38].
It is concluded that exogenous SOD treatment reduces
liver oxidative stress in diabetic animals and increases
antioxidant enzyme activity, despite not altering nuclear
transcription factor NFκB. Nevertheless,there is a signiﬁcant
change to p65 and iNOS, which justiﬁes the performance of
further studies in the use of exogenous antioxidants for DM
treatment.
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